ProCE Banner Activity

Trastuzumab Deruxtecan for Our Patients With HER2 Mutation–Positive Advanced NSCLC

Clinical Thought
Expert commentary by Matthew Gubens, MD, MS, a thoracic oncologist, and Craig Mackinnon, MD, PhD, an anatomical and molecular pathologist, on the recent FDA approval of trastuzumab deruxtecan for previously treated patients with HER2 mutation–positive advanced NSCLC.

Released: September 12, 2022

Expiration: September 11, 2023

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Alexander Craig Mackinnon, Jr.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Genentech TEXT Only

Janssen administered by Scientific Affairs

Lilly

Novartis Pharmaceuticals Corporation

Partners

AMP

ProCE Banner

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Cardinal Health, Genentech/Roche, Genzyme/Sanofi, Guardant, iTeos, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Craig Mackinnon, MD, PhD, has no relevant financial relationships to disclose.